|Description||Filaminast is a Type 4 cyclic nucleotide phosphodiesterase inhibitor. It is an analog of rolipram which served as a prototype molecule for several development efforts. In Oct 1999, phase II clinical trials for Asthma in European Union was discontinued.|
|Synonyms||UNII-CDD69JC61J; Way-pda-641; WAY-PDA 641; WAY-PDA-641; CDD69JC61J; SCHEMBL73843; 1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethanone-(E)-O-(aminocarbonyl)oxime|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Wyeth|
RPL 554 is a potent and selective PDE3/4 inhibitor for respiratory diseases, particularly in patients with asthma.
Sch59498 is a potent inhibitor of phosphodiesterase 1c (Pde1c) with antihypertensive and antiplatelet effect.
An orally active selective type 5 cGMP phosphodiesterase inhibitor.
Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
CP-461 free base
CP 461, belonging to a class of novel proapoptotic drugs with antineoplastic effect, specifically inhibit cyclic GMP phosphodiesterases but not cyclooxygenase-1...
Cilostamide is a selective and specific inhibitor of type III phosphodiesterase (PDE3). It shows moderate selectivity for PDE3A isozyme and PDE3B. It increases ...
Aminophylline is a competitive nonselective phosphodiesterase inhibitor with an IC50 of 0.12 mM and also a nonselective adenosine receptor antagonist.
The citrate salt form of Carbazeran, which has been found to be an aldehyde oxidase (AO) substrate as well as a non-specific PDE inhibitor.